11.1 Introduction to Parkinson’s Disease

Pathophysiology and Clinical Presentation of Parkinson's Disease

Parkinson's disease is a progressive neurological disorder that disrupts movement and, over time, cognition. At its core, the disease results from the death of dopamine-producing neurons in the brain, which throws off the delicate balance needed for smooth, coordinated movement. For nursing practice, understanding why these symptoms occur helps you anticipate patient needs and grasp how the drugs covered later in this unit actually work.

Mechanisms of Parkinson's Disease

The central problem in Parkinson's is the degeneration of dopaminergic neurons in a brain region called the substantia nigra pars compacta (SNpc). These neurons normally send dopamine to the striatum (made up of the caudate nucleus and putamen), which is part of the basal ganglia circuit that controls movement. As these neurons die, dopamine levels in the striatum drop, and the whole circuit malfunctions.

Several interconnected processes drive this neurodegeneration:

• Lewy body accumulation: Abnormal clumps of misfolded α-synuclein protein build up inside surviving neurons. These aggregates, called Lewy bodies, are toxic to cells and are found not only in the SNpc but also in the cortex, amygdala, and locus coeruleus, which helps explain why Parkinson's causes non-motor symptoms too.
• Nigrostriatal pathway damage: The pathway connecting the SNpc to the striatum degrades, impairing the initiation and control of voluntary movement. This is the direct cause of the hallmark motor symptoms: bradykinesia, rigidity, and tremor.
• Neurotransmitter imbalance: With less dopamine available, two things happen in the basal ganglia:
  • The indirect pathway (inhibitory) becomes overactive, leading to excessive inhibition of the thalamus and motor cortex.
  • The direct pathway (excitatory) becomes underactive, compounding the problem.
  • The balance between dopamine and other neurotransmitters, particularly acetylcholine, is also disrupted. This dopamine-acetylcholine imbalance is a key pharmacological target you'll see throughout this unit.
• Oxidative stress and mitochondrial dysfunction: Dopaminergic neurons are especially vulnerable to oxidative damage, and impaired mitochondrial function accelerates their death.

By the time motor symptoms appear, roughly 60–80% of dopaminergic neurons in the SNpc have already been lost. That's why early non-motor symptoms often precede the movement problems by years.

Symptoms of Parkinson's Disease

Parkinson's symptoms fall into three categories. You'll want to be familiar with all of them, since non-motor and physical signs are frequently tested and often overlooked in clinical settings.

Motor symptoms (the "cardinal" features):

• Bradykinesia: Slowness of movement and difficulty initiating tasks. Patients struggle with fine motor activities like buttoning shirts or tying shoelaces. This is the most functionally disabling motor symptom.
• Rigidity: Muscle stiffness with resistance to passive movement. Two patterns are described: "lead-pipe" rigidity (constant resistance) and "cogwheel" rigidity (ratchet-like catches during movement).
• Resting tremor: A 4–6 Hz tremor most prominent in the hands, often called a "pill-rolling" tremor. It's typically unilateral at onset and less common in the legs or jaw. The tremor decreases with intentional movement, which distinguishes it from essential tremor.
• Postural instability: Impaired balance and coordination with increased fall risk, especially in later stages.
• Gait disturbances: Shuffling gait, reduced arm swing, difficulty turning, and freezing of gait (sudden, brief inability to move, as if the feet are glued to the floor).

Non-motor symptoms:

• Cognitive impairment and dementia: Problems with attention, executive function, and memory. Dementia risk increases significantly in advanced stages.
• Depression and anxiety: These mood disorders can actually precede motor symptoms and significantly affect quality of life.
• Sleep disorders: REM sleep behavior disorder (physically acting out dreams), insomnia, and excessive daytime sleepiness.
• Autonomic dysfunction: Orthostatic hypotension (blood pressure drops when standing), constipation, and urinary urgency or frequency. These are important to monitor because many Parkinson's medications can worsen orthostatic hypotension.
• Olfactory dysfunction (hyposmia): Reduced sense of smell, often one of the earliest non-motor symptoms.

Physical signs to recognize in patients:

• Hypomimia: Reduced facial expression, giving a "masked" or "poker face" appearance
• Micrographia: Handwriting that becomes progressively smaller and more cramped
• Hypophonia: Soft, monotonous speech with reduced volume and inflection
• Sialorrhea (drooling): Caused by reduced swallowing frequency, not overproduction of saliva
• Stooped posture and festinating gait: Flexed posture with short, shuffling steps that tend to accelerate

Causes and Diagnosis of Parkinson's Disease

There is no single cause of Parkinson's. Most cases are idiopathic (no identifiable cause), but several risk factors are well established:

• Genetic factors: Familial Parkinson's accounts for about 5–10% of cases. Key gene mutations include SNCA, LRRK2, PRKN, PINK1, and DJ-1. Even in sporadic cases, certain genetic variations can increase susceptibility.
• Environmental factors: Exposure to pesticides (rotenone, paraquat), herbicides, and heavy metals (manganese) is associated with higher risk. Rural living and well-water consumption may increase exposure to these toxins.
• Aging: Risk increases with age, and the average onset is around 60 years. Age-related cellular changes in the brain likely contribute to vulnerability.

Diagnostic methods:

There is no single definitive test for Parkinson's. Diagnosis relies on a combination of clinical findings and supportive investigations:

1. Clinical assessment: A thorough medical history and neurological exam evaluating motor symptoms. The Unified Parkinson's Disease Rating Scale (UPDRS) is the standard tool, scoring speech, facial expression, tremor, rigidity, bradykinesia, and postural stability.

2. Neuroimaging:

   • DaT scan (SPECT): Measures dopamine transporter activity in the striatum. This is the most useful imaging test because it can differentiate Parkinson's from essential tremor and drug-induced parkinsonism.
   • MRI and CT: Used mainly to rule out other causes of parkinsonism, such as vascular parkinsonism, multiple system atrophy, or normal pressure hydrocephalus.

3. Levodopa challenge test: The patient is given levodopa (a dopamine precursor), and their response is observed. A significant improvement in motor symptoms (greater than 30% reduction in UPDRS score) supports a Parkinson's diagnosis.

4. Exclusion of other causes of parkinsonism: Several conditions mimic Parkinson's and must be ruled out:

   • Essential tremor: Involves action tremor (not resting tremor) and does not respond to levodopa
   • Drug-induced parkinsonism: Caused by dopamine-blocking medications like antipsychotics or antiemetics; resolves when the drug is stopped
   • Progressive supranuclear palsy: Features early postural instability, inability to look up or down (supranuclear gaze palsy), and poor levodopa response
   • Corticobasal degeneration: Presents with asymmetric apraxia, cortical sensory loss, and alien limb phenomenon alongside parkinsonian features

Historical and Cellular Aspects of Parkinson's Disease

Parkinson's disease was first described by James Parkinson in 1817 in his "Essay on the Shaking Palsy." The cellular hallmarks of the disease center on the substantia nigra, where dopaminergic neuron loss is visible even on gross examination (the region loses its characteristic dark pigmentation).

At the cellular level, several processes contribute to neurodegeneration beyond what's already been discussed:

• Oxidative stress is particularly damaging to dopaminergic neurons because dopamine metabolism itself generates reactive oxygen species.
• Mitochondrial dysfunction, specifically defects in Complex I of the electron transport chain, has been consistently found in Parkinson's patients and is thought to be both a cause and consequence of neuronal damage.
• The cumulative loss of dopaminergic input to the motor cortex via the basal ganglia circuit is what ultimately produces the movement impairments patients experience.